Interventional, Multicenter Study of Trastuzumab Deruxtecan Monotherapy in Patients With Unresectable and/or Metastatic HER2-Low or HER2 Immunohistochemistry 0 Breast Cancer: DESTINY-Breast15. Cancer Res 1 May 2024; 84 (9_Supplement): PO2–19–06. ...
此外,HER2 低表达状态是动态的,重复连续活检可增加三阴性乳腺癌(triple-negative breast cancer,TNBC)患者 HER2低表达检出率,从而提供有意义的临床信息[4]。目前,对于 HR 阴性 HER2 低表达的晚期乳腺癌患者在既往治疗上属于传统 TNBC ...
If yourbreast cancerhas a significant number of receptors for either estrogen or progesterone, it’s considered hormone-receptor positive. Tumors that are ER/PR-positive are much more likely to respond to hormone therapy than tumors that are ER/PR-negative. ...
and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial.” The Lancet. Oncology vol. 25,3 (2024): 317-325. doi:10.1016
e13030#Background:IHC/FISH is currently the gold standard method of HER2 expression assessment on breast cancer (BC) cells. Recent studies regarding HER2-low category show that the semi-quantitative methods are inaccurate. False-negative results may have a negative impact on the prognosis and ...
aAmong triple-negative breast cancers, HER2(0) breast cancer shows a strong tendency to be basal-like compared with HER2(1+) breast cancer: preliminary results. 在三倍消极乳腺癌之中, HER2( 0) 乳腺癌显示一个强的倾向是基础象比较HER2( 1+) 乳腺癌: 初步结果。[translate]...
[8] Schmid P, Cortés J, Marmé F, et al. 214MO Sacituzumab govitecan (SG) efficacy in hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (MBC) by HER2 immunohistochem...
Currently, the human epidermal growth factor receptor 2 (HER2) status of breast cancer is classified dichotomously as negative or positive to select patients for HER2-targeted therapy. However, with the introduction of novel treatment options, it is important to get more insight in the biology of...
6. Jerusalem G, et al. Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer. JAMA Oncol. 2018;4(10):1367–1374. 7. Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality wo...
Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer is the most prevalent type of breast cancer, in which endocrine therapy resistance and distant relapse remain unmet challenges. Accurate molecular classification is urgently required for guiding pre...